Table 4.
Safety assessment of two groups
| Safety assessment | DEB-TACE group | PVA-TACE group | P-value |
|---|---|---|---|
|
| |||
| Clinical toxicity (grade 1–2) | |||
| Fever (yes/no, %) | 16/10, 61.5/38.5 | 27/5, 84.4/15.6 | 0.048 |
| Abdominal pain (yes/no, %) | 22/4, 84.6/15.4 | 28/4, 87.5/12.5 | 1.000 |
| Vomiting (yes/no, %) | 3/23, 11.5/88.5 | 5/27, 15.6/84.4 | 1.000 |
| Clinical toxicity (grade 3–4) | |||
| GI bleeding (yes/no, %) | 1/25, 3.8/96.2 | 0/32, 0/100 | 0.448 |
| Unbearable pain or fever (yes/no, %) | 5/21, 19.2/80.8 | 8/24, 25.0/75.0 | 0.600 |
| Hepatic failure (yes/no, %) | 0/26, 0/100 | 0/32, 0/100 | NA |
| Laboratory toxicity (grade 1–2) | |||
| Increased transaminases (yes/no, %) | 12/14, 46.2/53.8 | 23/9, 71.9/28.1 | 0.046 |
| Increased bilirubin (yes/no, %) | 6/20, 23.1/76.9 | 7/25, 26.9/78.1 | 0.913 |
| Increased alkaline phosphatase (yes/no, %) | 3/23, 11.5/88.5 | 3/29, 9.4/90.6 | 1.000 |
| Laboratory toxicity (grade 3–4) | |||
| Increased transaminases (yes/no, %) | 5/21, 19.2/80.8 | 7/25, 21.9/78.1 | 0.805 |
| Increased bilirubin (yes/no, %) | 0/26, 0/100 | 1/31, 3.1/96.9 | 1.000 |
| Increased alkaline phosphatase (yes/no, %) | 0/26, 0/100 | 0/32, 0/100 | NA |
Abbreviations: DEB-TACE, transarterial chemoembolization with drug-eluting beads; GI, gastrointestinal; PVA-TACE, polyvinyl alcohol plus transarterial chemoembolization.